Back to today’s briefing

Story perspectives

FDA Bans Semaglutide Amid Drug Shortage; Lawsuit Filed

3/28/2025

48 4

Summary

Story summary

The FDA is set to ban compounded semaglutide, a key ingredient in popular weight loss medications Ozempic and Wegovy, now that a drug shortage has ended. In response, the Outsourcing Facilities Association has launched a lawsuit, emphasizing that many patients depend on these affordable alternatives. Meanwhile, ongoing safety concerns about compounded drugs further complicate patient access.

1 of 1

Story summary

The FDA is set to ban compounded semaglutide, a key ingredient in popular weight loss medications Ozempic and Wegovy, now that a drug shortage has ended. In response, the Outsourcing Facilities Association has launched a lawsuit, emphasizing that many patients depend on these affordable alternatives. Meanwhile, ongoing safety concerns about compounded drugs further complicate patient access.